Paratek Pharmaceuticals, Inc.
- Jurisdiction
United States - LEI
5493007V5QDIWECEYV79 - ISIN
US6993743029 (PRTK )- Sectors
Scores
- Fair value (Benjamin Graham formula)
- N/A
- Financial strength (Piotroski F-Value)
-
6
/ 9
- Fundamental strength relative to industry (Mohanram G-Value)
-
3
/ 7
Profile
Paratek Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of life-saving therapies for life-threatening diseases or other public health threats for civilian, government, and military use. Read full profile
Fundamentals
- Net revenue
€143.08M - Gross margin
84.9% - EBIT
-€37.99M - EBIT margin
-26.6% - Net income
-€57.25M - Net margin
-40.0%
Statement period: - (published )
Stock price
Dividends
- Last dividend amount
-
$0.06 - Ex date
-
Analyst ratings
No analyst ratings available
Insider Transactions
No insider transactions in the last 90 days. View older insider transactions
Earnings Calls
Earnings Calls
Latest earnings call: May 9, 2023 (Q1 2023)